Here we share the news and updates we don't want you to miss
The TCD QA Standards working group have published the 3rd Edition of Standards and Guidance in February 2026.
Learn more about the NHP Cellular Therapy Operational Group (CTG)
The guidance provides good practice advice for medical examiners on recognising the impact of SCD in various contexts including deaths and coroner referrals.
First iteration of the mortality reporting pathway for haemoglobinopathies.
Following the stepping down of Professor Baba Inusa, Dr Kate Gardner has been appointed the new NHP Chair.
Pfizer Shares Patient Advice Regarding Immediate Withdrawal of Voxelotor (Oxybryta®)
Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.
On 25th September 2024, Pfizer announced its voluntarily withdrawing of all lots of OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD).
On 08.08.2024 the National Institute for Health and Care Excellence (NICE) approves NHS use of Casgevy ™ [Exagamglogene Autotemcel (‘Exa-Cel’)] for treatment of Transfusion-dependent beta Thalassaemia
For World Sickle Cell Awareness Day (19th June) 2024, we ask; 'Why try to reinvent the wheel?'
The Founding Chair of the NHP, Professor Baba Inusa, announces his departure from the NHS and his NHP Role in March 2024.
Home
About
The MDT
Science & innovation
News & features
Events
Contact
The National Haemoglobinopathy Panel
Women’s and Children’s Academic Health - Kings College London
Becket House
1 Lambeth Palace Rd
London, SE1 7EU
